2020 Could Spell The End Of Mega-Mergers, For Now

Instead Expect A Wave Of Mid-Sized Deals In 2020, Industry Watchers Say

19 Feb 2020

Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.

PwC’s Pharma and Life Sciences group expects mid-sized biotechs developing life-saving drugs to be highly sought, while larger companies will continue divesting non-core assets to free up capital and narrow focus to core competencies and targeted growth areas.

PwC’s Global Pharma & Life Sciences Deals Insights Year-End 2019 & 2020 Outlook report suggests that 2020 will be a...